Drugs / BRII-5395
last change May 2026 re-read 2 minutes ago

BRII-5395

Developed for
hepatocellular carcinoma
Investigated by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Trials 1 · a red edge is where a trial was stopped

202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07557251 May 2026 → Dec 2028 expected hepatocellular carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BRII-5395 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07557251
Route Intramuscular “via IM injection” NCT07557251